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Abstract: Background and Objectives: Laparoscopic splenectom y (LS) has become the gold standard for 
patients w ith im mune thrombocytopenic purpura (ITP). The total rem ission rate after splenectom y is 
70% -90% , of w hich 66% is long-term . D espite this h igh response rate, som e patients do n ot benefit 
from  surgery. It is therefore im portant to try  to identify  risk factors for an  unsatisfactory clinical 
response. The aim of this study w as to assess long-term  outcom es of LS for ITP and identify factors 
associated w ith increased disease rem ission rates. M aterials and M ethods: We retrospectively studied 
consecutive patients w ith  ITP  undergoing L S in  a tertiary referral surgical center prospectively 
recorded in a database. Inclusion criteria were: Elective, laparoscopic splenectom y for diagnosed ITP, 
and com plete follow -up. The cohort w as divided into tw o groups— Group 1 (G1) patients w ith ITP 
remission after splenectomy and Group 2 (G2) patients w ithout remission. There were 113 G1 patients 
and 52 G2 patients. M edian follow -up w as 9.5 (IQ R: 5 -15 ) years. Results: In univariate analysis, 
patient's age, body mass index (BM I), preoperative platelet count, the need for platelet transfusions, 
and presence of hemorrhagic diathesis were shown to be statistically significant factors. Next, we built 
a m ultivariate logistic regression model using factors significant in univariate analysis. Age <41 years 
(odds ratio (OR) 4.49; 95%  CI: 1 .66-12.09), BM I <  24.3 kg/m 2 (OR: 4.67; 95%  CI: 1 .44-15.16), and 
preoperative platelet count > 97 X 103/m m 3 (OR: 3.50; 95% CI: 1.30-9.47) were shown to be independent 
prognostic factors for ITP  rem ission after LS. C onclusions: The independent prognostic factors for 
ITP rem ission after LS revealed in our study are: age <41 years, BM I <  24.3 kg/m2, and preoperative 
p latelet count > 97 X 103/m m 3. D uration of the ITP and the tim e of treatm ent are not related to 
rem ission after LS.
Keyw ords: splenectom y; ITP; im m une throm bocytopenia; laparoscopy; rem ission; long-term  
outcomes
1. Introduction
Im m une throm bocytopenic purpura (ITP) is a hem atological disorder characterized by 
autoim m une-m ediated  destruction of platelets and reduction of platelet production. In  general, 
the m ainstays of m edical therapy are corticosteroids and intravenous im m unoglobulins. H ow ever, 
long-term  rem ission rates are only 20%  to 25%  in adults [1,2]. Splenectom y is a m ain second-line 
treatm ent in  refractory ITP [3,4 ]. Since the very  first laparoscopic splenectom y w as carried out
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by D elaitre and M aignien in  1991, it has becom e the gold standard for patients w ith  ITP [5 ]. The 
total rem ission rate after splenectom y is 70% -90% , 66%  of w hom  have long-term  rem ission w ithout 
additional therapy [6] . Although the choice of surgical approach (laparoscopic) in case of splenectomy 
is straightforw ard due to the obvious benefits of m inim ally  invasive surgery, the decision about 
splenectom y tim ing itself is still difficult [7- 9]. The reason is that despite the h igh response rate of 
splenectomy, some patients do not benefit from surgery. For this reason, it seems reasonable to identify 
risk factors for satisfactory clinical response and failure in patients operated on for ITP. The aim of the 
study w as to assess long-term  outcomes of laparoscopic splenectom y (LS) for ITP and identify factors 
associated w ith increased rem ission rates.
2. M aterials and M ethods
2.1. Design
This w as a retrospective cohort study of consecutive patients w ith  ITP undergoing LS betw een 
1998 and 2017 in a tertiary referral, university-affiliated, surgical center, that w ere prospectively  
recorded in a database. Inclusion criteria were: Elective, laparoscopic splenectom y for diagnosed ITP, 
and com plete follow-up. Patients w ith unclear diagnosis of ITP, splenic traum a, initially subm itted to 
open surgery, partial resections and other spleen-preserving procedures w ere excluded from  further 
analyses. The entire cohort w as divided into two groups— Group 1 patients w ith ITP rem ission after 
splenectom y and G roup 2 patients w ithou t rem ission. A ll patients w ere follow ed up strictly for the 
first postoperative m onth. To collect long-term  data, w e contacted  the patients and checked their 
remission status. The minimal time interval between surgery and follow-up was one year after surgery.
2.2. Definitions
Sym ptom atic ITP is defined as throm bocytopenia associated w ith  petechiae or purpura, 
unusual/non-occasional hem atom as, persistent bleeding from  w ounds or other injuries, m ucosal 
bleeding, frequent or heavy epistaxis, and/or hemorrhage from any site (usually gingival or menorrhagia 
in wom en).
R em ission (response) w as defined as a p latelet count of >1 0 0  X 103/m m 3 in follow -up, no 
sym ptom s of ITP and bleedings at the time of follow-up, and no current or postoperative treatm ent of 
ITP. Non-rem ission (non-response) was defined as a lack of a rise in platelet count to 100 X 103/m m 3 or 
an initial rise bu t return to values <1 0 0  X 103/m m 3 postoperatively. The need to restart or continue 
steroids or other therapy to sustain normal platelet count or spontaneous bleeding w ithin 30 days after 
splenectom y was also considered non-rem ission (non-response). Additionally, we performed analyses 
for durable postoperative platelet count of >50  X 103/m m 3 in follow-up.
All patients w ere preoperatively assessed by a hem atologist and appropriate treatm ent introduced 
according to our predefined protocol [10]. O perative tim e m easurem ent w as m easured from  skin 
incision to closure. The intraoperative blood loss w as the am ount of blood aspirated by  the suction 
machine. Intraoperative adverse events were defined as any iatrogenic harmful event occurring during 
the operation not derived from  the standard course of operation. Intraoperative blood loss >5 0 0  mL 
w as considered to be hem orrhage, because losing less than one unit of b lood (500 m L) usually  does 
not negatively affect the condition of the patient and does not lead to hypovolem ia and hem orrhagic 
shock [11,12]. Perioperative m orbidity  w as defined as any com plication or deviation from  a routine 
postoperative course observed during 30 days after LS (graded with Clavien-D indo classification [13]). 
Postoperatively, patients w ere follow ed-up by a hem atologist or fam ily doctor.
2.3. Operative Technique
The prim ary choice in all cases w as four-port laparoscopic splenectomy. In the beginning of our 
experience in LS, we predom inantly used the “vessels first" technique, as described elsewhere [14,15].
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Later, the “hilar transection" technique w as used, as we have described previously [16]. Occasionally, 
the operator placed clips on larger vessel branches of the hilum  to ensure proper hem ostasis.
2.4. Ethics
This study m eets the Report of the ISPOR Task Force on Retrospective D atabases guidelines [17]. 
A ll procedures follow ed the ethical standards on hum an experim entation, both  institutional and 
national, including the Fortaleza revision of the 1975 Declaration of Helsinki. The study was approved 
by the B ioethical C om m ittee of the Jagiellonian  U niversity, Krakow , Poland (approval num ber 
1072/6120/160/2017 from 21 December 2017). Informed consent for the surgical treatm ent w as obtained 
from all patients before the procedure.
2.5. Statistical Analysis
D ata analyses w ere perform ed u sing Statsoft STA TISTICA  v.13.5 softw are (Statsoft Inc., Tulsa, 
O K, U SA ). C ontinuous variables are presented as m ean ±  standard deviation (SD) or m edian and 
interquartile range (IQ R), w hen appropriate. C ategorical variables w ere analyzed in Pearson 's 
chi-square test or chi-square w ith  Yates correction, w hen appropriate. The Shap iro-W ilk  test w as 
used to analyze if continuous variables w ere norm ally  distributed. C ontinuous data w as analyzed 
w ith  the Student's t-test (for norm ally  d istributed) and the M an n -W h itn ey  U  test (for non-norm ally  
distributed data). Finally, univariate and then m ultivariate logistic regression analyses w ere bu ilt in 
search of factors influencing odds ratios (OR) w ith  95%  confidence interval (95%  CI) of prim ary and 
secondary outcomes. Receiver operating characteristic (ROC) curves were used to set cut-off points in 
the process of conversion from  a continuous to a dichotom ous variable. A  K ap lan -M eier curve w as 
bu ilt for rem ission status w ith in  the study period. R esults w ere considered statistically significant 
w hen the p -value w as less than 0.05.
3. Results
Patients
A total of 165 patients w ith ITP fulfilling inclusion criteria w ere treated in our departm ent between 
1998 and 2017. Study groups consisted of 113 patients w ith ITP rem ission (Group 1) and 52 w ithout 
rem ission (Group 2). Baseline characteristics of the study cohort are presented in Table 1. M edian 
follow-up w as 9.5 (IQR: 5-15) years. There were no differences in gender between the groups. Patients 
in group 1 w ere significantly younger (p <  0.001), had a low er BM I (p =  0.002), and had a higher 
preoperative platelet am ount (p =  0.034).
C om plications occurred in 13 patients (7.88% ), w ith  nine (7.96% ) of them  in G roup 1 and four 
(7.69% ) in G roup 2 (Table 2 ). There w ere no conversions. O ne patient died after surgery due to a 
pulm onary em bolism , hence they w ere not observed long-term . The m edian hospital stay w as four 
days (IQR 3 -4 ), three days for Group 1 (IQR 3 -4 ), and four days for Group 2 (IQR 3-5).
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Table 1. Patients' characteristics.
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All n =  165 (100%) Group 1 n =  113 (68.48%)
Group 2 n =  52 
(31.52%) p-Value
Gender, n (%) male female 52 (32) 113 (68) 34 (30) 79 (70) 18 (35) 34 (65) 0.561
Age, median (IQR), years 35 (25-52) 31 (24-48) 50 (36.5-60) <0.001
BMI, median (IQR), kg/m2 25.69 (21.76-29.30) 24.30 (20.52-29.01) 27.65 (25.50-30.62) <0.001
Spleen size, median (IQR), cm 11 (10- 12) 11 (10- 12) 11 (10- 12) 0.599
Lowest preoperative platelet count, 
median (IQR), X103/mm3 8 (4-16) 10 (5-18) 7 (3-12) 0.071
Preoperative platelet count, 
median (IQR), X103/mm3 90 (48-119) 97 (50-125) 68.5 (36.5-107) 0.034
Preoperative steroids administration, n (%) 158 (95.76) 107 (94.69) 51 (98.08) 0.293
Immunoglobulin administration, n (%) 37 (22.42) 26 (23.01) 11 (21.15) 0.791
Preoperative platelet transfusions, n (%) 19 (11.52) 9 (7.96) 10 (19.23) 0.065
Accessory spleen, n (%) 36 (21.82) 25 (22.12) 11 (21.15) 0.950
Perioperative complications, n (%) 13 (7.88) 9 (7.96) 4 (7.69) 0.610
Blood transfusions, n (%) 3 (1.82) 1 (0 .88) 2 (2.85) 0.234
Time from diagnosis of ITP to procedures, 
median (IQR), months 24 (6.75-57) 18 (6.5-48) 24 (9-84) 0.241
Symptomatic ITP, n (%) 90 (54.55) 59 (52.21) 31 (59.62) 0.375
Preoperative time of conservative 
treatment, median (IQR), months 9.5 (5-30) 8.5 (4.5-24) 12 (5-51) 0.178
Table 2. Perioperative morbidity.
The K aplan-M eier curve dem onstrating probability of full rem ission against time of observation 
is presented in Figure ??.
U nivariate logistic regression identified factors that m ay im pact rem ission after L S  (Table 3 ). 
In univariate analysis, age, BM I, preoperative p latelet count, and the need for p latelet transfusions 
w ere found to be statistically significant. N ext, w e bu ilt m ultivariate logistic regression m odel using 
item s significant in  u nivariate analysis (Table 4 ) . C ontinuous variables used in univariate logistic 
regression m odels were dichotom ized using ROC analyses. Cut-o ff  points are shown in Table 4 . Area 
under curve (AUC) for age w as 0.72 (95% CI 0.63-0 .81, p  <  0.001), for BM I 0.71 (95% CI 0 .62-0 .80, p  <  
0.001), and for preoperative platelet count 0.61 (95%  CI 0 .51-0 .70 , p  =  0.030). A ge < 41 years, BM I <  
24.3 kg/m 2, and preoperative platelet count > 97 X 103/ m m 3 w ere shown to be independent prognostic 
factors for ITP rem ission after LS.
All Group 1 Group 2
Operative time, median (IQR), min 85 (65-105) 80 (60-100) 90(70-110)
Blood loss, median (IQR), mL 50 (20-100) 30 (10-50) 50 (20-100)
LOS, median (IQR), days 4(3-4) 3 (3-4) 4 (3-5)
Perioperative morbidity, n (%) 13 (7.88) 9 (7.96) 4 (7.69)
Clavien-Dindo Morbidity All Remission Non-remission
Illb Acute pancreatitis, 1 1 0sub-phrenic abscess
Gastric perforation, 1 1 0
sub-phrenic abscesses
Peritonitis, intra-abdominal 1 1 0abscesses
Intra-abdominal bleeding 5 2 3
Ilia Pancreatitis 1 0 1
II Pneumonia 2 2 0
Postoperative fever 1 1 0
I Sub-phrenic fluid collection 1 1 0
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Table 3. Univariate logistic regressio n model for factors potentially affecting remission of immune 
thrombocytopenic purpura (ITP) after laparoscopic splenectomy (LS).
OR 95% CI p-Value
Male/Female 1.23 0.61-2.49 0.561
Age, with every 1 year 0.94 0.93-0.97 <0.001
BMI, with every 1 kg/m2 0.85 0.77-0.93 <0.001
LOS, with every 1 day 0.82 0.59-1.16 0.263
Ultrasound length of spleen, with every cm 1.04 0.93-1.16 0.5022
Lowest preoperative platelet co u nt, with every 1 X  103/mm3 1.03 0.99-1.07 0.080
Preoperative platelet count, with every 1 X  103/mm3 1.01 i . 1 . 00 - 1.01 0.025
Preoperative steroids administration 0.35 i . 0.04-3.03 0.3037
Preoperative immunogaobulin administration 1.11 i. 0.50—20.49 0.79)1
Platelet transfusions 0.36 0.14-0.97 0.041
Additional spleen 1.06 0.47-2.37 0.889
Perioperative complications 1.03 0.30-3.56 0.952
Blood transfusions 0.22 0.02—21.57 0.223
Operative time, with every 1 min 0.99 i. 0.98-1.01 0.671
Blood loss, with ev/ry 1 mL 0.99 i . 0.98-1.01 0.696
Time from diagnosis of ITP to procedures, with every 1 month 0.99 0.99-1.00 0.396
Symptoms 0.74 0.38-1.45 0.376
Preoperative time of conservative treatment, with every 1 month 0.99 0.98-1.02 0.230
Table 4. Multivariate logistic regression model for factors potentially affecting remission of ITP after LS.
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OR 95% CI p-Value
Age <41 years 4.49 1.66-12.09 0.003
BMI <  24.3 kg/m2 4.67 1.44-15.16 0.010
Preoperative platelet 
count > 97 X  103/m m3
3.50 1.30-9.47 0.012
Platelet transfusions 0.75 0.21-2.75 0.665
Additionally, we perform ed logistic regression for possible risk factors for durable postoperative 
platelet count > 5 0  X 103/m m 3. Table 5  shows the results of univariate logistic regression m odels. Age, 
preoperative platelet count, and preoperative platelet transfusions were found to be significant factors 
in univariate m odels. ROC analyses were built to set cut-off points for continuous variables. AUC for 
patient's age w as 0.74 (95%  CI 0 .64-0 .84 , p  <  0.001), w hile for preoperative p latelet count it w as 0.55 
(95% CI 0 .41-0.69, p  =  0.047). Then they w ere used in m ultivariate logistic regression, as presented in 
Table 6. Age <42 years and a preoperative platelet count > 9 5  X 103/m m 3 were found to independently 
increase the odds ratio for durable postoperative platelet count above 50 X 103/m m 3.
Table 5. Univariate logistic regression model for factors potentially affecting postoperative platelet 
count >50 X  103/mm3.
OR 95% CI p-Value
Male/Female 1.44 0.49-4.23 0.505
Age, with every 1 year 0.95 0.92-0.98 0.001
BMI, with every 1 kg/m2 0.92 0.82-1.03 0.131
LOS, with every 1 day 1.02 0.73-1.45 0.889
Ultrasound length of spleen, with every cm 1.15 0.90-1.47 0.254
Lowest preoperative platelet count, with every 1 X  103/mm3 1.02 0.97-1.07 0.441
Preoperative platelet count, with every 1 X  103/mm3 1.03 1.00-1.06 0.010
Preoperative steroids administration 0.51 0.20-1.32 0.162
Preoperative immunoglobulin administration 0.63 0.22-1.80 0.635
Platelet transfusions 0.43 0.27-0.71 0.048
Additional spleen 1.67 0.46-6.11 0.435
Perioperative complications 2.43 0.01-4.65 0.981
Blood transfusions 0.37 0.67-1.69 0.695
Operative time, with every 1 min 0.99 0.97-1.03 0.113
Blood loss, with every 1 mL 1.00 0.99-1.04 0.607
Time from diagnosis of ITP to procedures, with every 1 month 1.00 0.99-1.06 0.945
Symptoms 0.98 0.38-2.55 0.966
Preoperative time of conservative treatment, with every 1 month 0.99 0.98-1.02 0.248
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Table 6. M ultivariate logistic regression model for factors potentially affecting postoperative 
PLT >  50 X  103/mm3.
OR 95% CI p-Value
Age <42 years 4.93 1.49-16.34 0.009
Preoperative platelet 
count > 95 X  103/m m3
3.45 1.03-11.59 0.043
Platelet transfusions 0.69 0.23-2.07 0.501
4. D iscussion
In  this study w e evaluated factors associated w ith  the long-term  rem ission of ITP after L S  to 
help surgeons to identify patients w ho are expected to benefit from  splenectomy. O ur study showed 
that an age <41  years, a BM I <  24.3 kg/m 2 and a preoperative p latelet count > 9 7  X 103/m m 3 are 
independent factors increasing chance for rem ission. Regarding durable postoperative platelets at a 
level of >50  X 103/m m 3, an age <42 years and a preoperative platelet count >95  X 103/m m 3 were found 
to independently increase odds ratios.
Laparoscopic splenectom y is a safe procedure w ith  low  m ortality  and m orbidity  rates bu t is 
not com pletely  free of com plications. A splenic patients are susceptible to opportunistic infections 
such as life-threatening, overw helm ing post-splenectom y infections (O PSI), w hich is w hy all patients 
should receive preoperative vaccines for encapsulated bacteria [18]. A ccording to A m erican Society 
of H em atologist (ASH ) 2011 guidelines, pneum ococcal and m eningococcal vaccinations for elective 
splenectom y are recom m ended and one dose of H. in fluenzae  type b vaccine is not contraindicated 
before splenectom y [19]. A particularly im portant factor is the increased risk of venous thromboembolic 
events. In a study by  Tastaldi et al. the perioperative m orbidity w as 7.3%, including three deep vein 
and tw o portal vein throm boses, one reoperation for bleeding, and no m ortalities [20] . In a study by 
Thai et al. ITP patients w ho underw ent splenectom y had a 16%  venous throm boem bolism  rate w hen 
com pared to a 2%  rate on a m atched cohort that w as not treated w ith  surgery [21]. O ther studies 
have show n that the risk for portal or splenic vein throm bosis after splenectom y w as estim ated to be 
0 .1-4/100 patient-years [22] . Com plications, as described in  a w ork by Rijcken et al. occurred in 6/73 
patients (8.2%), w hich consisted mostly of postoperative bleeding. Five patients (6.8%) required surgery 
for bleeding control. One patient had an epifascial wound infection after conversion. A limited pleural 
effusion developed in one patient [6]. In our study, com plications occurred in 13 (7.88%) patients. Nine 
(7.96%) of them occurred in the rem ission group and four (7.69%) in the non-rem ission group. There 
were no conversions. One patient died after surgery due to pulm onary embolism. Although morbidity 
rates w ere relatively low, prediction of the efficacy of LS for ITP is still im portant.
There is no doubt that laparoscopic splenectom y is a valuable and effective treatm ent of patients 
w ith ITP but there are still patients who have a poor long-term response. The present study showed that 
tw o-thirds of ITP patients achieved a long-term  response after LS during our follow -up periods and 
one third had no response. In a study by Tastaldi et al. after a m edian 62-m onth follow-up, two-thirds 
(68% ) of the patients experienced a sustained response and w ere treatm ent-free [20]. R ijcken et al. 
found stable rem ission in a total of 44/72 (61.1% ) patients [6]. Rui et al. show ed that a total of 65 
of 78 (83.3% ) patients had stable rem ission and no need for further therapy for ITP after L S [23]. 
Differences in hem atological outcomes m ight come from different definitions and clinical criteria used 
in different studies. W e defined the response to LS based on recent consensus criteria for com plete 
response (CR) as a platelet count of >100  X 103/m m 3 in follow -up [19]. How ever, it should be noted 
that studies like Istl et al. defined response to LS as a platelet count greater than 50 X 103/m m 3 w ith no 
need for postoperative m edical m anagem ent during the follow -up period [24], so w e also perform ed 
analyses for that cut-off point. Age and preoperative platelet count rem ained significant, independent 
prognostic factors.
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M any studies have attempted to indicate conclusive predictive factors of hem atological response 
to splenectom y. Patient age is the m ost acknow ledged predictive factor of successful outcom e after 
splenectom y. The analysis of D uperier et al. revealed that a younger age predicted a successful 
response to laparoscopic splenectom y specifically in patients younger than 50 years. Conversely, 
refractory as w ell as recurrent disease w ere seen in older patients [25].  D uperier et al. also revealed 
that an age younger than 50 years had a sensitivity of 72%, a specificity of 68% , a positive predictive 
value of 58% , and a negative predictive value of 77%  [25]. Tastaldi e t al. show ed that patients w ho 
sustained a long-term  response w ere younger (44.7 years ±  20.6 vs. 53.4 years ±  19.5, p  =  0.037) [20]. 
Other investigators Radaelli et al. [26] and Ojima et al. [3 ] have not found correlation between age and 
successful response to splenectomy.
Preoperative p latelet level has been  evaluated as a predictive factor by m any researchers. 
Rijcken et al. reported that patients w ith a high preoperative platelet count boosted w ith steroids and 
im m unoglobulins had a stable long-term  response [6] . O ther studies presented sim ilar results [20,23] . 
Duperier et al. revealed in a clinical study w ith a mean follow-up of 22 months that higher preoperative 
platelet levels predicted a successful response to LS regardless of how  this level w as achieved [25]. 
In our study the preoperative p latelet count > 9 7  X 103/m m 3 is a prognostic factor for ITP rem ission. 
O n the other hand O jim a et al. show ed that only a high p latelet count on  postoperative day seven 
w as associated w ith a good response to splenectom y [3] . It is w orth  considering that m aybe patients 
w ith initially higher platelet levels or those who respond to steroid therapy have less severe ITP. Other 
factors reported as successful predictors exam ined by some of investigators are disease duration from 
diagnosis to splenectom y, and splenic sequestration [27] .
Timing of LS is not standardized. M ost patients submitted to surgery have already failed in several 
m edical attem pts. They probably already have adverse effects such as hypertension, osteoporosis or 
infections [6]. In our study we observed that duration of ITP did not affect response to surgery. There 
is how ever one im portant factor that has not been  studied so far. We believe that conversion from  
responding to m edical treatm ent to a refractory course m ay be m ore im portant than the duration of 
the disease. A better outcome is expected in patients who can still achieve a high PLT level responding 
to m edical treatm ent and do not present adverse effects of m edications, w hich m ay be optim al tim ing 
for LS.
Another interesting aspect of this study was finding that accessory spleens were present in 21.82% 
patients in general, and this did not differ betw een groups. This seem s not to be a significant clinical 
finding, yet there w ere som e case reports about recurrent ITP [28,29].
The present study is lim ited by typical factors for a single-center retrospective analysis. It has a 
retrospective design. D ue to a long period of study duration (19 years) w e w ere not able to precisely 
analyze hematological preparation for surgery and preoperative conservative treatment. However, the 
study analyzes rem ission rates after splenectom y, not preoperative treatm ent. Indications have not 
changed over that tim e, w ith only patients unsuitable for further conservative treatm ent operated on. 
Follow -up is different m ostly  due to the tim e interval betw een the date of surgery and our analysis 
(follow -up). To collect long-term  data, w e contacted the patients and checked their rem ission status. 
The m inim al tim e interval betw een surgery and follow -up w as one year after surgery. Additionally, 
some patients were lost to follow up and w e did not include them  in the analysis. However, the study 
group is still relatively large and permitted the drawing of reliable results and conclusions. M oreover, 
patients w ere operated on by  several surgeons w ith different levels of experience. A nother lim itation 
w as that w e did not include potential postoperative com plications that m ight have occurred later 
than 30 days after discharge in  this analysis. Those com plications m ay have influenced the overall 
com plication rate.
5. Conclusions
Laparoscopic splenectom y is a safe and effective treatm ent of pharm acologically refractory ITP. 
The m ajority of patients achieved long-term  responses in this study. Independent prognostic factors for
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ITP rem ission after LS revealed in our study are: age <41  years, BM I <  24.3 kg/m 2, and preoperative 
p latelet count > 9 7  X 103/m m 3. D uration of ITP and treatm ent tim e w ere unrelated to rem ission after 
LS. Further studies are necessary to assess patient-related predictive factors of response to surgical 
therapy for determ ination of optim al approach and optim al surgical tim ing.
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